The market expects AC Immune (ACIU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus ...
AC Immune SA’s ACIU shares soared in the past three months, driven by rapid progress in the development of its lead pipeline candidate, ACI-24.060, for various neurodegenerative diseases. ACI-24.060 ...
AC Immune (ACIU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
The market expects AC Immune (ACIU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback